Denali Therapeutics Inc. $DNLI
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS7
PHASE 3 / 2-32
RECRUITING2
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO83%
Delay Index: of 6 active trials registered more than a year ago, 5 have moved their primary completion (readout) date by more than 6 months since first registration (median +24.0 months). See all sponsors →
Open Denali Therapeutics Inc. on the live radar map → 📅 $DNLI readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| DNL593 NCT05262023 |
P1/2 | Active, not recruiting | Frontotemporal Dementia | 85 | 2026-12 (+13 mo) |
| BIIB122 225 mg NCT06602193 |
P2 | Active, not recruiting | Parkinson Disease | 50 | 2027-03 (+10 mo) |
| tividenofusp alfa NCT06075537 |
P2/3 | Enrolling by invitation | Mucopolysaccharidosis II | 99 | 2027-06 |
| COMPASS NCT05371613 |
P2/3 | Active, not recruiting | Mucopolysaccharidosis II | 65 | 2027-12 (+24 mo) |
| DNL952 NCT07354724 |
P1/2 | Recruiting | Late-onset Pompe Disease | 32 | 2028-08 |
| tividenofusp alfa NCT04251026 |
P1/2 | Active, not recruiting | Mucopolysaccharidosis II | 47 | 2031-02 (+97 mo) |
| DNL126 NCT06181136 |
P1/2 | Recruiting | Mucopolysaccharidosis Type IIIA | 30 | 2032-07 (+47 mo) |